Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AZD0780 and DDI with Itraconazole, Carbamazepine, Midazolam, and EE/LNG
NCT06671405Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of laroprovstat in dyslipidemia (4 cohorts), sponsored by AstraZeneca. Primary endpoints: Area under concentration-time curve from time 0 to infinity, Area under concentration curve from time 0 to the last quantifiable concentration and 1 more. Started Sep 2024; status: completed.
02
Drugs
laroprovstat
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT06671405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06671405.